Modeling NSCLC progression: Recent advances and opportunities available

AAPS Journal

Volumn 15, Issue 2, 2013, Pages 542-550

  Suleiman, Ahmed Abbas ^a   Nogova, Lucia ^a   Fuhr, Uwe ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

disease progression; drug development; lung cancer; modeling; tumor growth

Indexed keywords

ANTIMETASTATIC AGENT; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GALUNISERTIB; GEFITINIB; GEMCITABINE; INHIBITOR OF TYPE I RECEPTOR TRANSFORMING GROWTH FACTOR BETA KINASE; MOTESANIB; PACLITAXEL; PEMETREXED; PLACEBO; SMAD PROTEIN; SORAFENIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL IMMORTALIZATION; COLORECTAL CANCER; COMPLEX MECHANISTIC MODEL; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LUNG NON SMALL CELL CANCER; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NONHUMAN; PERSONALIZED MEDICINE; PHARMACOKINETIC MODEL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; REVIEW; SEMI MECHANISTIC MODEL; SIMULATION; SURVIVAL RATE; TREATMENT DURATION; TUMOR CELL; TUMOR SEEDING; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DRUG DISCOVERY; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; RESEARCH DESIGN; TIME FACTORS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84877040641     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9461-y     Document Type: Review

References (85)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367-80.
4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-5.
5. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61(3):275-91.
6. FDA. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. 2004. http://www.fda.gov/ScienceResearch/ SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262. htm. Accessed 10 December 2012.
7. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: Opportunities and challenges. Nat Rev Clin Oncol. 2009;6(5):259-65.
8. Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: A multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol. 2008;48(5):632-49.
9. Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, et al. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn. 2005;32(2):185-97.
10. Rombout F, Aarons L, Karlsson M, Man A, Mentre F, Nygren P, et al. Modelling and simulation in the development and use of anti-cancer agents: An underused tool? J Pharmacokinet Pharmacodyn. 2004;31(6):419-40.
11. Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak. 2008;8:6.
12. Noble SL, Sherer E, Hannemann RE, Ramkrishna D, Vik T, Rundell AE. Using adaptive model predictive control to customize maintenance therapy chemotherapeutic dosing for childhood acute lymphoblastic leukemia. J Theor Biol. 2010;264(3):990-1002.
13. Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit. 2011;33(1):99-107.
14. Maitland ML, Schilsky RL. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011;61(6):365-81.
15. Mould DR. Developing models of disease progression. In: Ette E, Williams P, editors. Pharmacometrics: The science of quantitative pharmacology. Hoboken: Wiley; 2007. p. 547-82.
16. Holford NH, Mould DR, Peck CC. Disease progress models. In: Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Markey SP, editors. Principles of clinical pharmacology. 2nd ed. Burlington: Academic; 2007. p. 313-21.
17. Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB. The time course of drug effects. Pharm Stat. 2009;8(3):176-85.
18. Chan PL, Holford NH. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol. 2001;41:625-59.
19. Sheiner LB. Is intent-to-treat analysis always (ever) enough? Br J Clin Pharmacol. 2002;54(2):203-11.
20. Mould DR. Models for disease progression: new approaches and uses. Clin Pharmacol Ther. 2012;92(1):125-31.
21. Holford NH, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A. 1992;89(23):11466-70.
22. Frey N, Laveille C, Paraire M, Francillard M, Holford NH, Jochemsen R. Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol. 2003;55(2):147-57.
23. Pors Nielsen S, Barenholdt O, Hermansen F, Munk-Jensen N. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol. 1994;101(4):319-24.
24. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003;9(11):4227-39.
25. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84(10):1424-31.
26. Bajzer Z, Marušić M, Vuk-Pavlović S. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math Comput Model. 1996;23(6):31-46.
27. Jusko WJ. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci. 1971;60(6):892-5.
28. Harashima H, Iida S, Urakami Y, Tsuchihashi M, Kiwada H. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. J Control Release. 1999;61(1-2):93-106.
29. Ozawa S, Sugiyama Y, Mitsuhashi Y, Kobayashi T, Inaba M. Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product. Cancer Chemother Pharmacol. 1988;21(3):185-90.
30. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res. 1993;53(17):3964-7.
31. Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature. 1976;264(5586):542-5.
32. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48(24 Pt 1):7067-71.
33. Bernard A, Kimko H, Mital D, Poggesi I. Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development. Expert Opin Drug Metab Toxicol. 2012;8(9):1057-69.
34. Schabel Jr FM. Concepts for systemic treatment of micrometastases. Cancer. 1975;35(1):15-24.
35. Frances N, Meille C, Hoffman G, Lave T, Walz A. Integrating distribution to tumor tissue into a dynamic PK/PD model to evaluate the anticancer effect of erlotinib in patient-derived LXFA677 tumor xenograft mice. PAGE Meeting 2011. Abstract 2174.
36. Traina TA, Dugan U, Higgins B, Kolinsky K, Theodoulou M, Hudis CA, et al. Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling. Breast Dis. 2010;31(1):7-18.
37. Glatt S, Pitou C, Yingling J, Bueno L, Alwis Dd, Troconiz IF. Preclinical Population PK/PD of TGF beta RI Kinase Inhibitor for Cancer. PAGE Meeting 2005. Abstract 771.
38. Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol. 2007;47:357-400.
39. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64(3):1094-101.
40. Bueno L, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008;44(1):142-50.
41. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-91.
42. Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, et al. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clin Cancer Res. 2008;14(13):4213-8.
43. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009;86(2):167-74.
44. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: From black and white to shades of grey. Nat Rev Cancer. 2006;6(5):409-14.
45. Lavin PT. An alternative model for the evaluation of antitumor activity. Cancer Clin Trials. 1981;4(4):451-7.
46. Bruno R, Claret L. On the use of change in tumor size to predict survival in clinical oncology studies: Toward a new paradigm to design and evaluate phase II studies. Clin Pharmacol Ther. 2009;86(2):136-8.
47. Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res. 2000;17(11):1335-44.
48. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation. AAPS J. 2005;7(3):E544-59.
49. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-50.
50. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-703.
51. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-39.
52. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):e17.
53. Norton L, Massague J. Is cancer a disease of self-seeding? Nat Med. 2006;12(8):875-8.
54. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315-26.
55. Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8(6):369-77.
56. Poggesi I, de Nicolao G, Germani M, Rocchetti M. Re: Antitumor efficacy testing in rodents. J Natl Cancer Inst. 2009;101(22):1592-3. author reply 3-4.
57. Simeoni M, De Nicolao G, Magni P, Rocchetti M, Poggesi I. Modeling of human tumor xenografts and dose rationale in oncology. Drug Discov Today Technol. 2012. doi: 10.1016/j.ddtec.2012.07.004.
58. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008;29(4):186-91.
59. Barrett JS, Gupta M, Mondick JT. Model-based drug development applied to oncology. Expert Opin Drug Discov. 2007;2(2):185-209.
60. Rocchetti M, Simeoni M, Pesenti E, De Nicolao G, Poggesi I. Predicting the active doses in humans from animal studies: A novel approach in oncology. Eur J Cancer. 2007;43(12):1862-8.
61. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov. 2006;5(9):741-54.
62. Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 2006;66(7):3355-8. discussion 8-9.
63. Hryniuk WM. More is better. J Clin Oncol. 1988;6(9):1365-7.
64. Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997;15(5):1858-69.
65. Cannistra SA. Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol. 2008;26(22):3665-7.
66. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-16.
67. Bruno R, Lu JF, Sun YN, Claret L. A modeling and simulation framework to support early clinical drug development decisions in oncology. J Clin Pharmacol. 2011;51(1):6-8.
68. Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol. 2009;27(25):4103-8.
69. Claret L, Girard P, O'shaughnessy J, Hoff P, Van Cutsem E, Blum J, et al. Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent. ASCO Meeting Abstracts. 2006;24(18-suppl):6025.
70. Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol. 2009;49:291-301.
71. Claret L, Lu JF, Bruno R, Hsu CP, Hei YJ, Sun YN. Simulations Using a Drug-Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non-Small-Cell Lung Cancer. Clin Pharmacol Ther. 2012;92(5):631-4.
72. Blumenschein Jr GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011;22(9):2057-67.
73. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012;30(23):2829-36.
74. Sharma MR, Maitland ML, Ratain MJ. Models of excellence: Improving oncology drug development. Clin Pharmacol Ther. 2012;92(5):548-50.
75. Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007;99(19):1455-61.
76. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST. J Clin Oncol. 2004;22(22):4442-5.
77. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427-34.
78. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505-12.
79. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA. 2003;290(16):2149-58.
80. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21(12):2237-46.
81. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol. 2004;22(5):777-84.
82. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol. 2004;22(5):785-94.
83. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29(13):1701-8.
84. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27(3):439-45.
85. Schindler E, Westwood P, Amantea M, Hansson EK, Milligan PA, Karlsson MO, et al. PKPD-Modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib. PAGE Meeting 2012. Abstract 2595.